Publication
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (3)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 3
- cancerMalignant Colorectal Neoplasmcivic_curation1.00
- geneBRAFcivic_curation1.00
- variantBRAF Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (10)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 21641636
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EGFR Overexpression + KRAS MutationEGFRKRAS3 | ||||||||
| Cetuximab | Colorectal Adenocarcinoma | Predictive | B | Supports Adverse Response | 3 | submitted | EID11059The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC | civic |
| (prognostic) | Colorectal Adenocarcinoma | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID11058The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC | civic |
| Cetuximab + ChemotherapyCombination | Colorectal Adenocarcinoma | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID11062The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC | civic |
| KRAS G12 + KRAS G13 + KRAS Q612 | ||||||||
| (prognostic) | Colorectal Adenocarcinoma | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID11056The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC | civic |
| Cetuximab + ChemotherapyCombination | Colorectal Adenocarcinoma | Predictive | B | Does Not Support Sensitivity Response | 4 | submitted | EID11055The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC | civic |
| KRAS G13D1 | ||||||||
| Cetuximab + ChemotherapyCombination | Colorectal Adenocarcinoma | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID11054The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC | civic |
| KRAS Wildtype1 | ||||||||
| Cetuximab + ChemotherapyCombination | Colorectal Adenocarcinoma | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID11057The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC | civic |
| BRAF D594G + BRAF V600E + KRAS MutationBRAFKRAS1 | ||||||||
| Cetuximab + ChemotherapyCombination | Colorectal Adenocarcinoma | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID11060The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC | civic |
| BRAF Mutation + KRAS Mutation + NRAS MutationKRASNRASBRAF1 | ||||||||
| (prognostic) | Colorectal Adenocarcinoma | Prognostic | B | Supports Poor Outcome | 4 | submitted | EID11061The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC | civic |
| BRAF Mutation1 | ||||||||
| (prognostic) | Malignant Colorectal NeoplasmCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID7158In the Medical Research Council (MRC) COIN trial, ISRCTN27286448, patients who presented with advanced colorectal cancer were randomly assigned to chemotherapy (oxaliplatin and fluoropyrimidine; arm A… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC | civic |